Podium to Practice: Chicago 2026 – LUNG: ABBV-706
OR
Studies / Trials Discussed
8008 – ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).
Chair
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
8008 – ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.